Johnson & Johnson's Janssen Biotech Inc. unit partnered with Metamark to identify cancer targets using Metamark's Prognosis Determinant discovery technology

Metamark Genetics Inc.

U.S. / Medical Devices and Diagnostics

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Johnson & Johnson

U.S. / Large-Cap Biopharma (>=$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced